EPO and chronic kidney disease: The introduction of erythropoietin-stimulating agents (ESAs) in the 1980s represented a major therapeutic advance for renal anemia, significantly enhancing the quality of life in end-stage renal disease (ESRD) patients while reducing dependence on blood transfusions (Costa et al., 2008).